Cases & Deals

  • Home
  • Practices
  • Allorion Therapeutics announces exclusive option and global license agreement for preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca

Share

Allorion Therapeutics announces exclusive option and global license agreement for preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca

January 2024

Client(s) Allorion Therapeutics, Inc.

Jones Day represents Allorion Therapeutics in patent matters and assisted in defending the intellectual property diligence in the company's exclusive option and global license deal of preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.